Novo Nordisk A/S (BCBA:NVO)

Market Cap	300.56T +2.4%
Revenue (ttm)	74.58T +5.6%
Net Income	26.36T +4.8%
EPS	5,930.67 +5.0%
Shares Out	n/a
PE Ratio	11.40
Forward PE	14.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,836
Open	10,590
Previous Close	10,540
Day's Range	10,150 - 10,590
52-Week Range	8,940 - 11,920
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 66,700
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: NVO

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 14, 2026

Data Sources Report a data error